This webcast features: Yiyu Dong, PhD, Associate Director of Viral Vector Process Technology Development (VVPTD), WuXi Advanced Therapies. Due to their capability for long-term transgene expression, large packaging capacity and ability to transduce postmitotic and quiescent cells, lentiviral vectors have become increasingly popular gene delivery tools for cell and gene therapies in recent years. However, capacity for lentiviral vector manufacture is a major industry bottleneck. WuXi Advanced Therapies has developed a lentiviral suspension manufacturing platform using OXGENE’s XLenti™ packaging plasmids.…
Monday, April 18, 2022 Daily Archives
Advanced-Therapy Automation Capabilities Can Increase Efficiencies and Reduce Costs
The cell and gene therapy (CGT) industry has grown out of disparate groups of developers, suppliers, and service providers. Players in the sector must collaborate if we expect to commercialize new therapies at scale. Despite concerted efforts in the field, however, the critical question of how to automate CGT production has yet to be answered. Without automated processes in place, the sector risks spiraling costs and operational inefficiencies that could inhibit patient access to much-needed therapies. Understanding such concerns, several…
Ask the Expert: In-Line Concentration Measurement for Adaptive Control of Downstream Processes
In-line process analytical technologies (PATs) hold much promise for enhancing control of biopharmaceutical manufacturing processes and, in turn, increasing process quality and reproducibility. During a January 2022 presentation, Ramsey Shanbaky (associate director of bioprocess applications at Repligen) described how his company’s CTech FlowVPX system for in-line protein concentration measurement enhances monitoring of downstream processes. Shanbaky’s Presentation Scientists often use ultraviolet–visible spectroscopy (UV-vis) to measure protein concentration in a drug substance (DS) or product (DP). Most UV-vis instruments determine that by…